A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.

[1]  Derek E. Smith,et al.  ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  B. Solomon,et al.  Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer , 2019, Cancers.

[3]  Jia Huang,et al.  Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1‐Rearranged Non–Small Cell Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  N. Pavlakis,et al.  ROS1‐Rearranged Non–Small‐Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses , 2018, Clinical lung cancer.

[5]  K. Syrigos,et al.  Khorana Score: Νew Predictor of Early Mortality in Patients With Lung Adenocarcinoma , 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[6]  C. Tromeur,et al.  Risk of venous thromboembolism in association with factor V leiden in cancer patients – The EDITH case-control study , 2018, PloS one.

[7]  Yuan Zhang,et al.  Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer , 2018, Respiratory Research.

[8]  H. Batura-Gabryel,et al.  Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients , 2018, Medical Oncology.

[9]  S. Schulman,et al.  Management of recurrent venous thromboembolism in patients with cancer: A review. , 2018, Thrombosis research.

[10]  H. Abdel-Razeq,et al.  Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! , 2018, Thrombosis Journal.

[11]  O. Melander,et al.  Factor V Leiden paradox in a middle-aged Swedish population: A prospective study , 2018, Vascular medicine.

[12]  B. Hughes,et al.  An analysis of incidental and symptomatic pulmonary embolism (PE) in medical oncology patients , 2017, Asia-Pacific journal of clinical oncology.

[13]  M. Tsao,et al.  ALK‐Rearranged Non–Small‐Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism , 2017, Clinical lung cancer.

[14]  T. Clackson,et al.  Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.

[15]  K. Hood,et al.  Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Mansfield,et al.  Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer , 2016, Journal of thrombosis and haemostasis : JTH.

[17]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[18]  Jean Mosser,et al.  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.

[19]  M. Socinski,et al.  Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. , 2016, The Lancet. Oncology.

[20]  R. Chiari,et al.  Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma. , 2015, Thrombosis research.

[21]  C. Marosi,et al.  Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS) , 2015, Journal of thrombosis and haemostasis : JTH.

[22]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[23]  D. Keeling,et al.  Diagnosis and management of heritable thrombophilias , 2014, BMJ : British Medical Journal.

[24]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[25]  O. Dekkers,et al.  Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta‐analysis , 2014, Journal of thrombosis and haemostasis : JTH.

[26]  T. Bilfinger,et al.  A systematic review of pulmonary embolism in patients with lung cancer. , 2012, The Annals of thoracic surgery.

[27]  J. Ahn,et al.  Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy. , 2010, Lung cancer.

[28]  V. Tagalakis,et al.  High Risk of Deep Vein Thrombosis in Patients with Non-small Cell Lung Cancer: A Cohort Study of 493 Patients , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  F. Rosendaal,et al.  The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality , 2005, Annals of Internal Medicine.

[30]  J. Olsen,et al.  Prognosis of cancers associated with venous thromboembolism. , 2000, The New England journal of medicine.

[31]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[32]  J. Clegg,et al.  World distribution of factor V Leiden , 1995, The Lancet.

[33]  B. Solomon,et al.  Thromboembolism in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. , 2018, Clinical lung cancer.